Journal of International Oncology ›› 2023, Vol. 50 ›› Issue (1): 1-11.doi: 10.3760/cma.j.cn371439-20221021-00001
Received:2022-10-21
Revised:2022-11-28
Online:2023-01-08
Published:2023-03-16
"
| 患者因素 | 不宜使用标准剂量顺铂治疗 | 需谨慎顺铂治疗 |
|---|---|---|
| 年龄（岁） | N/A | >70 |
| ECOG PS评分 | ≥2 | ≥1 |
| 营养不良（分） | N/A | PG-SGA评分≥3 |
| 合并症 | ||
| 肾功能不全 | Ccr<50 ml/min | Ccr：50~60 ml/min |
| 神经系统疾病 | ≥2级 | 1级 |
| 既往听力丧失/耳鸣 | ≥2级 | 1级 |
| 心功能不全 | NYHA心功能分级≥Ⅱ级 | NYHA心功能分级Ⅰ级 |
| HIV/AIDS | N/A | CD4+ T淋巴细胞计数<200个/μl |
| 既往铂类药物治疗（包括诱导化疗） | N/A | 顺铂累积剂量≥200 mg/m2 |
"
| 出现次数 | 剂量调整 |
|---|---|
| 第1次 | 暂停西妥昔单抗治疗≤21 d直到皮疹降至2级。如改善，可重新开始250 mg/m2西妥昔单抗治疗；如无改善，暂停治疗 |
| 第2次 | 暂停西妥昔单抗治疗≤21 d直到皮疹降至2级。如改善，调整剂量为200 mg/m2西妥昔单抗治疗；如无改善，暂停治疗 |
| 第3次 | 暂停西妥昔单抗治疗≤21 d直到皮疹降至2级。如改善，调整剂量为150 mg/m2西妥昔单抗治疗；如无改善，暂停治疗 |
| 第4次 | 永久性停用西妥昔单抗 |
"
| 分级 | 评判标准 | 基于分级的处理意见 |
|---|---|---|
| 1级 | 轻微红或干性脱皮 | 每周随访1次 |
| 2级 | 中度红斑和（或）干性脱皮；斑片状湿性脱皮，或局限于皮肤皱襞的非出血性结痂 | 每周随访2次 ①干性脱皮无结痂：短期（1~2周）使用糖皮质激素乳膏，怀疑二重感染的使用抗生素；②皮肤皱襞湿性脱皮：每天使用糖皮质激素乳膏（1~2周）减轻炎症反应，出现任何双重感染迹象时，局部使用针对金黄色葡萄球菌的抗生素。如二重感染加重，考虑全身使用抗生素，软锌制剂可用于皮肤皱襞，但应在放疗前将其去除以避免辐射剂量学问题，也可以使用伊红；③皮肤皱襞的非出血性结痂：同②的处理，此外，凝胶可用于结痂处 |
| 3级 | 湿性脱皮或出血性结痂；皮肤皱襞以外的非出血性结痂，但大部分局限于皮肤皱襞；轻微擦伤引起的出血；需要口服抗生素的二重感染 | 评估每天随访的必要性，密切监测局部或全身感染，如发生在<50 Gy，考虑短暂中断治疗 ①无结痂的湿性脱皮：外用抗菌剂，短期（1~2周）使用糖皮质激素乳膏，怀疑二重感染的使用抗生素，口服抗生素无效的考虑改静脉使用，软锌制剂可用于皮肤皱襞，但应在放疗前将其去除以避免辐射剂量学问题，也可以使用伊红；②有结痂的湿性脱皮：外用抗菌剂，怀疑二重感染的使用抗生素，口服抗生素无效的考虑改静脉使用，凝胶可用于结痂处，避免皮肤外伤以防止重复感染，如果使用水胶体敷料，在进行放疗剂量测定时应考虑敷料的厚度。放疗结束后可使用水纤维敷料 |
| 4级 | 危及生命；广泛的出血性结痂或溃疡（面积>50%）；受累部位大量自发性出血（>40%受累部位）；全真皮层皮肤坏死或溃疡或任何大小的溃疡，伴有广泛组织、肌肉、骨骼或支撑结构的坏死，伴有或不伴有全层皮肤受损；有皮肤移植指征；需要静脉使用抗生素的多重感染性溃疡 | 同时中断放疗和西妥昔单抗，西妥昔单抗需中断至皮炎恢复至2级或以下；严重二重感染口服抗生素无效的考虑改静脉使用；住院治疗 |
| [1] |
Machiels JP, René Leemans C, Golusinski W, et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2020, 31(11): 1462-1475. DOI: 10.1016/j.annonc.2020.07.011.
doi: 10.1016/j.annonc.2020.07.011 pmid: 33239190 |
| [2] |
Argiris A, Karamouzis MV, Raben D, et al. Head and neck cancer[J]. Lancet, 2008, 371(9625): 1695-1709. DOI: 10.1016/S0140-6736(08)60728-X.
doi: 10.1016/S0140-6736(08)60728-X pmid: 18486742 |
| [3] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
doi: 10.3322/caac.21660 |
| [4] |
Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2(1): 1-9. DOI: 10.1016/j.jncc.2022.02.002.
doi: 10.1016/j.jncc.2022.02.002 |
| [5] | 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)头颈部肿瘤诊疗指南2022[M]. 北京: 人民卫生出版社, 2022. |
| [6] |
Lacas B, Carmel A, Landais C, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group[J]. Radiother Oncol, 2021, 156: 281-293. DOI: 10.1016/j.radonc.2021.01.013.
doi: 10.1016/j.radonc.2021.01.013 pmid: 33515668 |
| [7] |
Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas[J]. J Clin Oncol, 2006, 24(25): 4170-4176. DOI: 10.1200/JCO.2006.07.2587.
doi: 10.1200/JCO.2006.07.2587 pmid: 16943533 |
| [8] |
Akimoto T, Hunter NR, Buchmiller L, et al. Inverse relationship between epidermal growth factor receptor expression and radiocu-rability of murine carcinomas[J]. Clin Cancer Res, 1999, 5(10): 2884-2890.
pmid: 10537357 |
| [9] |
Milas L, Mason K, Hunter N, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody[J]. Clin Cancer Res, 2000, 6(2): 701-708.
pmid: 10690556 |
| [10] |
Chen DJ, Nirodi CS. The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage[J]. Clin Cancer Res, 2007, 13(22 Pt 1):6555-6560. DOI: 10.1158/1078-0432.CCR-07-1610.
doi: 10.1158/1078-0432.CCR-07-1610 pmid: 18006754 |
| [11] |
Kurai J, Chikumi H, Hashimoto K, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines[J]. Clin Cancer Res, 2007, 13(5): 1552-1561. DOI: 10.1158/1078-0432.CCR-06-1726.
doi: 10.1158/1078-0432.CCR-06-1726 pmid: 17332301 |
| [12] |
Trivedi S, Srivastava RM, Concha-Benavente F, et al. Anti-EGFR targeted monoclonal antibody isotype influences antitumor cellular immunity in head and neck cancer patients[J]. Clin Cancer Res, 2016, 22(21): 5229-5237. DOI: 10.1158/1078-0432.CCR-15-2971.
doi: 10.1158/1078-0432.CCR-15-2971 pmid: 27217441 |
| [13] |
Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck[J]. Cancer Res, 1999, 59(8): 1935-1940.
pmid: 10213503 |
| [14] |
Herbst RS, Hong WK. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer[J]. Semin Oncol, 2002, 29(< W>5 Suppl 14): 18-30. DOI: 10.1053/sonc.2002.35644.
doi: 10.1053/sonc.2002.35644 |
| [15] |
Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers[J]. Semin Oncol, 2002, 29(< W>1 Suppl 4): 27-36. DOI: 10.1053/sonc.2002.31525.
doi: 10.1053/sonc.2002.31525 |
| [16] |
Kimura H, Sakai K, Arao T, et al. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor[J]. Cancer Sci, 2007, 98(8): 1275-1280. DOI: 10.1111/j.1349-7006.2007.00510.x.
doi: 10.1111/j.1349-7006.2007.00510.x |
| [17] |
Srivastava RM, Lee SC, Andrade Filho PA, et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients[J]. Clin Cancer Res, 2013, 19(7): 1858-1872. DOI: 10.1158/1078-0432.CCR-12-2426.
doi: 10.1158/1078-0432.CCR-12-2426 pmid: 23444227 |
| [18] |
Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck[J]. N Engl J Med, 2006, 354(6): 567-578. DOI: 10.1056/NEJMoa053422.
doi: 10.1056/NEJMoa053422 |
| [19] |
Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetu-ximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival[J]. Lancet Oncol, 2010, 11(1): 21-28. DOI: 10.1016/S1470-2045(09)70311-0.
doi: 10.1016/S1470-2045(09)70311-0 pmid: 19897418 |
| [20] | 国家药品监督管理局. 2022年06月20日药品批准证明文件待领取信息发布[EB/OL]. [2022-06-20]. https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20220620141308104.html. |
| [21] |
Mateo C, Moreno E, Amour K, et al. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity[J]. Immunotechnology, 1997, 3(1): 71-81. DOI: 10.1016/S1380-2933(97)00065-1.
doi: 10.1016/S1380-2933(97)00065-1 pmid: 9154469 |
| [22] | 国家卫生健康委办公厅. 新型抗肿瘤药物临床应用指导原则(2021年版)[EB/OL]. [2021-12-27]. http://www.nhc.gov.cn/yzygj/s7659/202112/0fbf3f04092b4d67be3b3e89040d8489.shtml. |
| [23] |
Schneider-Merck T, Lammerts van Bueren JJ, Berger S, et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage[J]. J Immunol, 2010, 184(1): 512-520. DOI: 10.4049/jimmunol.0900847.
doi: 10.4049/jimmunol.0900847 pmid: 19949082 |
| [24] |
Nguyen-Tan PF, Zhang Q, Ang KK, et al. Randomized phase Ⅲ trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity[J]. J Clin Oncol, 2014, 32(34): 3858-3866. DOI: 10.1200/JCO.2014.55.3925.
doi: 10.1200/JCO.2014.55.3925 pmid: 25366680 |
| [25] |
Le X, Hanna EY. Optimal regimen of cisplatin in squamous cell carcinoma of head and neck yet to be determined[J]. Ann Transl Med, 2018, 6(11): 229. DOI: 10.21037/atm.2018.05.10.
doi: 10.21037/atm.2018.05.10 pmid: 30023392 |
| [26] |
Loong HH, Ma BB, Leung SF, et al. Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma[J]. Radiother Oncol, 2012, 104(3): 300-304. DOI: 10.1016/j.radonc.2011.12.022.
doi: 10.1016/j.radonc.2011.12.022 pmid: 22300609 |
| [27] |
Nakano K, Sato Y, Toshiyasu T, et al. Predictive factors of head and neck squamous cell carcinoma patient tolerance to high-dose cisplatin in concurrent chemoradiotherapy[J]. Mol Clin Oncol, 2016, 4(2): 303-309. DOI: 10.3892/mco.2015.687.
doi: 10.3892/mco.2015.687 pmid: 26893880 |
| [28] |
Nuyts S, Dirix P, Clement PM, et al. Impact of adding concomitant chemotherapy to hyperfractionated accelerated radiotherapy for advanced head-and-neck squamous cell carcinoma[J]. Int J Radiat Oncol Biol Phys, 2009, 73(4): 1088-1095. DOI: 10.1016/j.ijrobp.2008.05.042.
doi: 10.1016/j.ijrobp.2008.05.042 |
| [29] |
Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis[J]. J Clin Oncol, 2008, 26(21): 3582-3589. DOI: 10.1200/JCO.2007.14.8841.
doi: 10.1200/JCO.2007.14.8841 pmid: 18559875 |
| [30] |
Noronha V, Joshi A, Patil VM, et al. Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase Ⅲ randomized noninferiority trial[J]. J Clin Oncol, 2018, 36(11): 1064-1072. DOI: 10.1200/JCO.2017.74.9457.
doi: 10.1200/JCO.2017.74.9457 pmid: 29220295 |
| [31] |
Sharma A, Kumar M, Bhasker S, et al. An open-label, noninfe-riority phase Ⅲ RCT of weekly versus three weekly cisplatin and radical radiotherapy in locally advanced head and neck squamous cell carcinoma (ConCERT trial)[J]. J Clin Oncol, 2022, 40(16_suppl): 6004. DOI: 10.1200/JCO.2022.40.16_suppl.6004.
doi: 10.1200/JCO.2022.40.16_suppl.6004 |
| [32] |
Ahn MJ, D'Cruz A, Vermorken JB, et al. Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: a literature review[J]. Oral Oncol, 2016, 53: 10-16. DOI: 10.1016/j.oraloncology.2015.11.019.
doi: 10.1016/j.oraloncology.2015.11.019 |
| [33] |
McCusker MG, Mehra R, Amr S, et al. Comparison of efficacy and toxicity of chemoradiation regimens for head and neck squamous cell carcinoma primary treatment[J]. Head Neck, 2022, 44(3): 749-759. DOI: 10.1002/hed.26965.
doi: 10.1002/hed.26965 |
| [34] |
Hamauchi S, Yokota T, Mizumachi T, et al. Safety and efficacy of concurrent carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin[J]. Int J Clin Oncol, 2019, 24(5): 468-475. DOI: 10.1007/s10147-018-01392-9.
doi: 10.1007/s10147-018-01392-9 pmid: 30656463 |
| [35] |
Giralt J, Trigo J, Nuyts S, et al. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial[J]. Lancet Oncol, 2015, 16(2): 221-232. DOI: 10.1016/S1470-2045(14)71200-8.
doi: 10.1016/S1470-2045(14)71200-8 pmid: 25596659 |
| [36] |
Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer[J]. N Engl J Med, 2010, 363(1): 24-35. DOI: 10.1056/NEJMoa0912217.
doi: 10.1056/NEJMoa0912217 |
| [37] |
Gillison ML, Trotti AM, Harris J, et al. Radiotherapy plus cetu-ximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial[J]. Lancet, 2019, 393(10166): 40-50. DOI: 10.1016/S0140-6736(18)32779-X.
doi: S0140-6736(18)32779-X pmid: 30449625 |
| [38] |
Mehanna H, Robinson M, Hartley A, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial[J]. Lancet, 2019, 393(10166): 51-60. DOI: 10.1016/S0140-6736(18)32752-1.
doi: S0140-6736(18)32752-1 pmid: 30449623 |
| [39] |
Rischin D, King MT, Kenny LM, et al. Randomized trial of radiotherapy with weekly cisplatin or cetuximab in low risk HPV associated oropharyngeal cancer (TROG 12.01): a Trans-Tasman Radiation Oncology Group study[J]. J Clin Oncol, 2021, 39(15_suppl): 6012. DOI: 10.1200/JCO.2021.39.15_suppl.6012.
doi: 10.1200/JCO.2021.39.15_suppl.6012 |
| [40] |
Rischin D, Mehanna H, Young RJ, et al. Prognostic stratification of HPV-associated oropharyngeal cancer based on CD103+ immune cell abundance in patients treated on TROG 12.01 and De-ESCALaTE randomized trials[J]. Ann Oncol, 2022, 33(8): 804-813. DOI: 10.1016/j.annonc.2022.04.074.
doi: 10.1016/j.annonc.2022.04.074 pmid: 35525376 |
| [41] |
Ang KK, Zhang Q, Rosenthal DI, et al. Randomized phase Ⅲ trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage Ⅲ to Ⅳ head and neck carcinoma: RTOG 0522[J]. J Clin Oncol, 2014, 32(27): 2940-2950. DOI: 10.1200/JCO.2013.53.5633.
doi: 10.1200/JCO.2013.53.5633 |
| [42] |
Weidhaas JB, Harris J, Schaue D, et al. The KRAS-variant and cetuximab response in head and neck squamous cell cancer: a secondary analysis of a randomized clinical trial[J]. JAMA Oncol, 2017, 3(4): 483-491. DOI: 10.1001/jamaoncol.2016.5478.
doi: 10.1001/jamaoncol.2016.5478 pmid: 28006059 |
| [43] |
顾湘, 刘坤, 苟浩成, 等. T4b期下咽癌非手术综合治疗77例回顾性分析[J]. 中华耳鼻咽喉头颈外科杂志, 2022, 57(1): 22-28. DOI: 10.3760/cma.j.cn115330-20210630-00407.
doi: 10.3760/cma.j.cn115330-20210630-00407 |
| [44] |
Patil VM, Noronha V, Joshi A, et al. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer[J]. Cancer, 2019, 125(18): 3184-3197. DOI: 10.1002/cncr.32179.
doi: 10.1002/cncr.32179 pmid: 31150120 |
| [45] |
Mesía R, Henke M, Fortin A, et al. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial[J]. Lancet Oncol, 2015, 16(2): 208-220. DOI: 10.1016/S1470-2045(14)71198-2.
doi: 10.1016/S1470-2045(14)71198-2 pmid: 25596660 |
| [46] |
Ghi MG, Paccagnella A, Ferrari D, et al. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase Ⅱ-Ⅲ trial[J]. Ann Oncol, 2017, 28(9): 2206-2212. DOI: 10.1093/annonc/mdx299.
doi: 10.1093/annonc/mdx299 pmid: 28911070 |
| [47] |
Lefebvre JL, Pointreau Y, Rolland F, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase Ⅱ study[J]. J Clin Oncol, 2013, 31(7): 853-859. DOI: 10.1200/JCO.2012.42.3988.
doi: 10.1200/JCO.2012.42.3988 pmid: 23341517 |
| [48] |
Janoray G, Pointreau Y, Alfonsi M, et al. Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal/hypopharyngeal cancer: long-term results of the TREMPLIN randomised GORTEC trial[J]. Eur J Cancer, 2020, 133: 86-93. DOI: 10.1016/j.ejca.2020.04.009.
doi: S0959-8049(20)30207-0 pmid: 32454417 |
| [49] |
Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer[J]. N Engl J Med, 2007, 357(17): 1695-1704. DOI: 10.1056/NEJMoa071028.
doi: 10.1056/NEJMoa071028 |
| [50] |
Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer[J]. N Engl J Med, 2007, 357(17): 1705-1715. DOI: 10.1056/NEJMoa070956.
doi: 10.1056/NEJMoa070956 |
| [51] |
Haddad R, O'Neill A, Rabinowits G, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial[J]. Lancet Oncol, 2013, 14(3): 257-264. DOI: 10.1016/S1470-2045(13)70011-1.
doi: 10.1016/S1470-2045(13)70011-1 pmid: 23414589 |
| [52] |
Cohen EE, Karrison TG, Kocherginsky M, et al. Phase Ⅲ rando-mized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer[J]. J Clin Oncol, 2014, 32(25): 2735-2743. DOI: 10.1200/JCO.2013.54.6309.
doi: 10.1200/JCO.2013.54.6309 pmid: 25049329 |
| [53] |
Geoffrois L, Martin L, De Raucourt D, et al. Induction chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas: results of the GORTEC 2007-02 phase Ⅲ randomized trial[J]. J Clin Oncol, 2018, 36(31): 3077-3083. DOI: 10.1200/JCO.2017.76.2591.
doi: 10.1200/JCO.2017.76.2591 pmid: 30016178 |
| [54] |
Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer[J]. N Engl J Med, 1991, 324(24): 1685-1690. DOI: 10.1056/NEJM199106133242402.
doi: 10.1056/NEJM199106133242402 |
| [55] |
Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase Ⅲ trial. EORTC Head and Neck Cancer Cooperative Group[J]. J Natl Cancer Inst, 1996, 88(13): 890-899. DOI: 10.1093/jnci/88.13.890.
doi: 10.1093/jnci/88.13.890 pmid: 8656441 |
| [56] |
Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer[J]. N Engl J Med, 2003, 349(22): 2091-2098. DOI: 10.1056/NEJMoa031317.
doi: 10.1056/NEJMoa031317 |
| [57] |
Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer[J]. J Clin Oncol, 2013, 31(7): 845-852. DOI: 10.1200/JCO.2012.43.6097.
doi: 10.1200/JCO.2012.43.6097 pmid: 23182993 |
| [58] |
Argiris A, Heron DE, Smith RP, et al. Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer[J]. J Clin Oncol, 2010, 28(36): 5294-5300. DOI: 10.1200/JCO.2010.30.6423.
doi: 10.1200/JCO.2010.30.6423 pmid: 21079141 |
| [59] |
Dietz A, Wichmann G, Kuhnt T, et al. Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-Ⅱ[J]. Ann Oncol, 2018, 29(10): 2105-2114. DOI: 10.1093/annonc/mdy332.
doi: S0923-7534(19)34205-X pmid: 30412221 |
| [60] |
Keil F, Hartl M, Altorjai G, et al. Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: results of a randomised phase Ⅱ AGMT trial[J]. Eur J Cancer, 2021, 151: 201-210. DOI: 10.1016/j.ejca.2021.03.051.
doi: 10.1016/j.ejca.2021.03.051 |
| [61] |
Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors[J]. Nat Rev Cancer, 2006, 6(10): 803-812. DOI: 10.1038/nrc1970.
doi: 10.1038/nrc1970 pmid: 16990857 |
| [62] |
Pinto C, Barone CA, Girolomoni G, et al. Management of skin reactions during cetuximab treatment in association with chemotherapy or radiotherapy: update of the Italian expert recommendations[J]. Am J Clin Oncol, 2016, 39(4): 407-415. DOI: 10.1097/COC.0000000000000291.
doi: 10.1097/COC.0000000000000291 |
| [63] |
郭晔, 张陈平. 抗EGFR单抗治疗复发/转移性头颈部鳞状细胞癌临床共识(2021年版)[J]. 中国癌症杂志, 2021, 31(12): 1220-1232. DOI: 10.19401/j.cnki.1007-3639.2021.12.011.
doi: 10.19401/j.cnki.1007-3639.2021.12.011 |
| [64] |
王刚, 项蕾红, 袁瑛, 等. 抗EGFR单抗治疗相关皮肤不良反应临床处理专家共识[J]. 实用肿瘤杂志, 2021, 36(3): 195-201. DOI: 10.13267/j.cnki.syzlzz.2021.042.
doi: 10.13267/j.cnki.syzlzz.2021.042 |
| [65] |
Vera-Llonch M, Oster G, Hagiwara M, et al. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma[J]. Cancer, 2006, 106(2): 329-336. DOI: 10.1002/cncr.21622.
doi: 10.1002/cncr.21622 pmid: 16342066 |
| [66] |
Elting LS, Cooksley CD, Chambers MS, et al. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies[J]. Int J Radiat Oncol Biol Phys, 2007, 68(4): 1110-1120. DOI: 10.1016/j.ijrobp.2007.01.053.
doi: 10.1016/j.ijrobp.2007.01.053 |
| [67] |
中国临床肿瘤学会抗肿瘤药物安全管理专家委员会, 中国临床肿瘤学会肿瘤支持与康复治疗专家委员会. 抗肿瘤治疗引起急性口腔黏膜炎的诊断和防治专家共识[J]. 临床肿瘤学杂志, 2021, 26(5): 449-459. DOI: 10.3969/j.issn.1009-0460.2021.05.011.
doi: 10.3969/j.issn.1009-0460.2021.05.011 |
| [68] |
Peterson DE, Bensadoun RJ, Roila F, et al. Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines[J]. Ann Oncol, 2011, 22 Suppl 6(Suppl 6): vi78-vi84. DOI: 10.1093/annonc/mdr391.
doi: 10.1093/annonc/mdr391 |
| [69] |
吴桐, 程斌. 肿瘤放化疗性口腔黏膜炎的防与治[J]. 中华口腔医学杂志, 2022, 57(4): 436-440. DOI: 10.3760/cma.j.cn112144-20220130-00038.
doi: 10.3760/cma.j.cn112144-20220130-00038 |
| [70] |
Duncan GG, Epstein JB, Tu D, et al. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis[J]. Head Neck, 2005, 27(5): 421-428. DOI: 10.1002/hed.20162.
doi: 10.1002/hed.20162 |
| [71] |
Elad S, Cheng KKF, Lalla RV, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy[J]. Cancer, 2020, 126(19): 4423-4431. DOI: 10.1002/cncr.33100.
doi: 10.1002/cncr.33100 |
| [72] |
中华医学会放射肿瘤治疗学分会. 放射性口腔黏膜炎防治策略专家共识(2019)[J]. 中华放射肿瘤学杂志, 2019, 28(9): 641-647. DOI: 10.3760/cma.j.issn.1004-4221.2019.09.001.
doi: 10.3760/cma.j.issn.1004-4221.2019.09.001 |
| [73] |
Bernier J, Russi EG, Homey B, et al. Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines[J]. Ann Oncol, 2011, 22(10): 2191-2200. DOI: 10.1093/annonc/mdr139.
doi: 10.1093/annonc/mdr139 pmid: 21606209 |
| [74] |
Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck[J]. N Engl J Med, 2016, 375(19): 1856-1867. DOI: 10.1056/NEJMoa1602252.
doi: 10.1056/NEJMoa1602252 |
| [75] |
Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study[J]. Lancet, 2019, 394(10212): 1915-1928. DOI: 10.1016/S0140-6736(19)32591-7.
doi: S0140-6736(19)32591-7 pmid: 31679945 |
| [76] |
Lee NY, Ferris RL, Psyrri A, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial[J]. Lancet Oncol, 2021, 22(4): 450-462. DOI: 10.1016/S1470-2045(20)30737-3.
doi: 10.1016/S1470-2045(20)30737-3 |
| [77] |
Machiels J, Tao Y, Burtness B, et al. LBA5-Primary results of the phase Ⅲ KEYNOTE-412 study: pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)[J]. Ann Oncol, 2022, 33(suppl_7): S808-S869. DOI: 10.1016/annonc/annonc1089.
doi: 10.1016/annonc/annonc1089 |
| [78] |
Bourhis J, Tao Y, Sun X, et al. LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): randomized phase Ⅲ GORTEC-REACH trial[J]. Ann Oncol, 2021, 32(SUPPLEMENT 5): S1310. DOI: 10.1016/j.annonc.2021.08.2112.
doi: 10.1016/j.annonc.2021.08.2112 |
| [79] |
Bonomo P, Desideri I, Loi M, et al. Anti PD-L1 durvalumab combined with cetuximab and radiotherapy in locally advanced squamous cell carcinoma of the head and neck: a phase Ⅰ/Ⅱ study (DUCRO)[J]. Clin Transl Radiat Oncol, 2018, 9: 42-47. DOI: 10.1016/j.ctro.2018.01.005.
doi: 10.1016/j.ctro.2018.01.005 |
| [80] |
Bonomo P, Desideri I, Mangoni M, et al. Durvalumab with cetu-ximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: a phase 1/2 trial[J]. Radiother Oncol, 2022, 169: 64-70. DOI: 10.1016/j.radonc.2022.02.008.
doi: 10.1016/j.radonc.2022.02.008 |
| [81] |
Ferris RL, Moskovitz J, Kunning S, et al. Phase Ⅰ trial of cetu-ximab, radiotherapy, and ipilimumab in locally advanced head and neck cancer[J]. Clin Cancer Res, 2022, 28(7): 1335-1344. DOI: 10.1158/1078-0432.CCR-21-0426.
doi: 10.1158/1078-0432.CCR-21-0426 |
| [82] |
Overgaard J, Hansen HS, Overgaard M, et al. A randomized double-blind phase Ⅲ study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85[J]. Radiother Oncol, 1998, 46(2): 135-146. DOI: 10.1016/s0167-8140(97)00220-x.
doi: 10.1016/s0167-8140(97)00220-x pmid: 9510041 |
| [83] |
Sun XS, Tao Y, Le Tourneau C, et al. Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study[J]. Lancet Oncol, 2020, 21(9): 1173-1187. DOI: 10.1016/S1470-2045(20)30327-2.
doi: 10.1016/S1470-2045(20)30327-2 |
| [84] |
Bourhis J, Burtness B, Licitra LF, et al. Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase Ⅲ study design[J]. Future Oncol, 2022, 18(14): 1669-1678. DOI: 10.2217/fon-2021-1634.
doi: 10.2217/fon-2021-1634 pmid: 35172587 |
| No related articles found! |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
